VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRCTPROCEPT BioRobotics Corporation
$22.56$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPRCTCash Flow

PROCEPT BioRobotics Corporation (PRCT) Cash Flow Statement

7Y historyFree accessUpdated daily

Free cash flow remains deeply negative at -49.4% of revenue in 2026Q1, reflecting the ongoing capital-intensive nature of scaling the AquaBeam robotic platform.

PRCT Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations-70.13M-48.98M-99.21M-108M-80.38M-57.33M-48.34M-43.82M
Operating CF Margin %--15.9%-44.19%-79.3%-107.16%-166.32%-626.45%-710.29%
Operating CF Growth %12.69%50.63%8.14%-34.36%-40.2%-18.6%-10.33%-
Net Income-102.47M-95.57M-91.41M-105.9M-87.15M-59.85M-53.02M-41.98M
Depreciation & Amortization6.65M6.39M5.23M3.81M2.84M3.32M2.86M1.49M
Stock-Based Compensation50.57M47.6M31.84M19.13M10.34M3.8M2.17M1.99M
Deferred Taxes00000451K00
Other Non-Cash Items-21.03M433K2.45M1.11M5.08M-345K126K-1.8M
Working Capital Changes-3.85M-7.84M-47.33M-26.16M-11.49M-4.71M-483K-3.53M
Change in Receivables-18.14M-898K-35.96M-33.1M-10.81M-2.91M-511K522K
Change in Inventory-7.94M-14.5M-17.23M-9.75M-15.25M-6.12M-3.1M-5.07M
Change in Payables5.22M6.65M-2.15M5.79M3.96M812K-205K-260K
Cash from Investing-10.43M-9.36M-4.41M-25.21M-2.65M-592K-233K43.15M
Capital Expenditures-10.43M-9.36M-4.41M-25.21M-2.65M-592K-233K-7.61M
CapEx % of Revenue3.24%3.04%1.96%18.51%3.54%1.72%3.02%123.37%
Acquisitions00000000
Investments--------
Other Investing00000000
Cash from Financing10.12M11.19M180.13M167.79M3.61M262.12M106.77M26.53M
Debt Issued (Net)00001.2M024.68M24.53M
Equity Issued (Net)4.44M11.19M164.52M161.71M0257.07M76.49M0
Dividends Paid00000000
Share Repurchases00000000
Other Financing5.68M015.6M6.09M2.42M5.04M5.6M1.99M
Net Change in Cash-70.56M-47.22M76.5M34.59M-79.42M204.19M58.2M25.86M
Free Cash Flow-80.57M-58.34M-103.62M-133.21M-83.03M-57.93M-48.58M-51.43M
FCF Margin %-25.02%-18.94%-46.16%-97.81%-110.69%-168.03%-629.47%-833.67%
FCF Growth %8.66%43.7%22.21%-60.43%-43.35%-19.25%5.55%-
FCF per Share-1.43-1.05-1.99-2.82-1.87-1.33-1.38-1.53
FCF Conversion (FCF/Net Income)0.79x0.51x1.09x1.02x0.92x0.96x0.91x1.04x
Interest Paid1.75M0004.29M03.97M397K
Taxes Paid00000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Persistent cash burn trajectory

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Disconnect

Based on reported financial statements, PRCT exhibits a volatile relationship between net income and operating cash flow, with the OCF/NI ratio fluctuating significantly, reaching 1.21 in 2026Q1, which suggests that non-cash adjustments and working capital swings are currently masking the underlying operational cash generation profile.

The frequent divergence between net losses and operating cash flow indicates that the company's cash burn is heavily influenced by factors beyond simple accounting losses. Investors should monitor whether this volatility stabilizes as the business model shifts toward recurring revenue, as current fluctuations may obscure the true cost of scaling the commercial infrastructure.

Free Cash Flow Margin Pressures

As indicated by quarterly data, PRCT's free cash flow margins remain deeply negative, bottoming at -76.9% in 2024Q1 and remaining at -49.4% in 2026Q1, highlighting a persistent inability to generate self-sustaining cash flow despite the ongoing expansion of the installed base of robotic systems.

The persistent negative FCF trajectory suggests that the capital-intensive nature of the business model, combined with high operating expenses, continues to outpace the cash generated from consumable sales. This trend warrants further investigation into the timing of when the company might reach a cash-flow-neutral state, given the current reliance on external funding.

Working Capital Volatility Impacts Liquidity

According to historical cash flow filings, working capital changes have been highly erratic, including a significant $25.0 million outflow in 2024Q4 followed by an $8.0 million inflow in 2025Q4, suggesting that inventory management and accounts receivable cycles are creating unpredictable impacts on the company's quarterly liquidity.

These swings in working capital appear to reflect the lumpy nature of capital equipment sales and the potential buildup of inventory to support future installations. Such variability makes it difficult to forecast short-term cash needs and suggests that the company's cash position remains sensitive to the timing of large hospital procurement cycles.

SBC Obscuring True Cash Burn

Data from recent SEC filings reveals that stock-based compensation has steadily increased to $13.1 million in 2026Q1, a non-cash expense that effectively masks the true magnitude of the company's operational cash burn and complicates the assessment of the actual runway available for commercial scaling activities.

While SBC is a standard tool for talent retention in high-growth medical technology, its rising scale suggests that the company's reported cash flow figures may be flattering the underlying operational reality. Analysts should adjust for these non-cash charges to better understand the true economic cost of the current growth strategy.

PRCT — Frequently Asked Questions

Quick answers to the most common questions about buying PRCT stock.

How much cash does PROCEPT BioRobotics Corporation (PRCT) generate from operations?

PROCEPT BioRobotics Corporation (PRCT) generated $-49.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is PROCEPT BioRobotics Corporation's free cash flow?

PROCEPT BioRobotics Corporation (PRCT) reported negative free cash flow of $58.3M in 2025, indicating capital requirements exceeded cash from operations.

What is PROCEPT BioRobotics Corporation's capital expenditure (CapEx)?

PROCEPT BioRobotics Corporation (PRCT) spent $9.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.